ZALTRAP® (aflibercept) added to survival time when given along with FOLFIRI to colorectal cancer patients who had already progressed on earlier oxaliplatin treatment.

On April 26, 2011, sanofi-aventis and Regeneron Pharmaceuticals announced positive results for the Phase III VELOUR trial, which compared ZALTRAP to a placebo during FOLFIRI chemotherapy.

Detailed results will be available at an upcoming medical conference. Read the rest of this entry »